Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting
The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Daniel H. Solomon¹, Peter Libby², Qiuquing Wang³, Katherine E Wolski⁴, Lisa M Wisniewski⁴, Neville Yeomans⁵, Michael Lincoff⁶, Steven E Nissen⁷ and M. Elaine Husni⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Western Sydney Medical School, Sydney, Australia, ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Neda Amiri¹, Gretchen Bandoli², Diana L Johnson² and Christina D. Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
Abstract Number: 2657 • 2016 ACR/ARHP Annual Meeting
Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity
Dong Jin Go^1,2, Kichul Shin³, Han Joo Baek⁴, Seong-Wook Kang⁵, Young Mo Kang⁶, Jae-Bum Jun⁷, Yun Jong Lee⁸, Sung-Hwan Park⁹ and Yeong Wook Song^10,11, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ⁸Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea
Background/Purpose: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving joint pain in rheumatoid arthritis (RA) patients, long-term use of NSAIDs can cause adverse effects.…
Abstract Number: 1439 • 2015 ACR/ARHP Annual Meeting
Reducing Gastric Ulcers in Patients with a History of Gastrointestinal (GI) Ulcers Who Require Long-Term High-Dose Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy
John Fort¹, Robert J. Holt², Jeffrey D. Kent³ and Alfonso Bello⁴, ¹POZEN Inc., Chapel Hill, NC, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Horizon Pharma USA, Inc., Deerfield, IL, ⁴Illinois Bone & Joint Inst, Glenview, IL
Background/Purpose: Patients ≥65 taking naproxen with previous GI symptoms have a 29% annual incidence of significant upper gastrointestinal events.(1) Those patients who are older, with…
Abstract Number: 2235 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities
Jeffrey N. Katz¹, Savannah Smith², Jamie E. Collins³, Joanne M. Jordan⁴, David J. Hunter⁵, Edward H. Yelin⁶, Lisa Suter⁷, A. David Paltiel⁸ and Elena Losina³, ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁷Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT, ⁸Yale School of Public Health, New Haven, CT
Background/Purpose: Because older patients with osteoarthritis (OA) and multiple comorbidities face high risk of toxicity from nonselective non-steroidal antiinflammatory drugs (NSAIDs) and Cox-2 inhibitors, opiates…
Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting
Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis
Sonia Jain¹, Charat Thongprayoon², Raul Espinosa¹, Sharonne Hayes¹, Kyle Klarich¹, Kevin Moder³, Nandan Anavekar¹, Jae Oh¹ and Eric L. Matteson⁴, ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting
A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes
Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
Abstract Number: 243 • 2014 ACR/ARHP Annual Meeting
Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study
Roy Altman¹, Allan Gibofsky², Marc C. Hochberg³, Byron Cryer⁴, Alan J. Kivitz⁵, Vibeke Strand⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Stanford University, Palo Alto, CA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Osteoarthritis (OA) is a frequent cause of disability in adults. NSAIDs such as diclofenac are often prescribed to treat OA pain. However, NSAIDs…
Abstract Number: 2047 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Combined Safety From Two Phase 3 Studies In Patients With Acute Pain Following Elective Surgery
Allan Gibofsky¹, Roy D. Altman², Clarence Young³, Daniel Solorio⁴ and Jennifer Nezzer⁵, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³Iroko Pharmaceuticals, Philadelphia, PA, ⁴Iroko Pharmaceuticals, LLC, Philadelphia, PA, ⁵Premier Research, Philadelphia, PA
Background/Purpose: Indomethacin is prescribed to treat acute pain and inflammation but, like other NSAIDs, is associated with dose-dependent gastrointestinal, cardiovascular, and renal adverse events (AEs).…
Abstract Number: 1095 • 2013 ACR/ARHP Annual Meeting
Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel 1% In Subjects With Acute Pain
Roy D. Altman¹, Helmut Pabst², Hans-Georg Predel³, Bruno Giannetti⁴, Ian Burnett⁵, Morris Gold⁶ and Evan F. Ekman⁷, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Independent Physician, Gilching, Germany, ³German Sports University, Cologne, Germany, ⁴CRM clinical trials GmbH, Rheinbach, Germany, ⁵Novartis Consumer Health, Nyon, Switzerland, ⁶Novartis Consumer Health, Parsippany, NJ, ⁷Southern Orthopaedic Sports Medicine, Columbia, SC
Background/Purpose: Diclofenac sodium topical gel (DSG) 1% is clinically proven to be effective and well-tolerated for treatment of osteoarthritis pain and could be appropriate to…
Abstract Number: 2681 • 2013 ACR/ARHP Annual Meeting
Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use
Jenny Brouwer^1,2, Johanna MW Hazes¹, Joop SE Laven² and Radboud JEM Dolhain¹, ¹Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months. During this period RA…
Abstract Number: 2149 • 2013 ACR/ARHP Annual Meeting
Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To 12 Weeks In Patients With Osteoarthritis
Clarence Young¹ and Marc C. Hochberg², ¹Iroko Pharmaceuticals, Philadelphia, PA, ²Medicine, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis (OA) is the most common cause of disability in the US and is frequently managed with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs, including diclofenac,…
Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies
Roy D. Altman¹, Allan Gibofsky², Mark Jaros³ and Clarence Young⁴, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Summit Analytical, Denver, CO, ⁴Iroko Pharmaceuticals, Philadelphia, PA
Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
Abstract Number: 415 • 2012 ACR/ARHP Annual Meeting
Hypoxia-Induced Endogenous Prostaglandin E2 Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue
Hirofumi Mitomi¹, Hidehiro Yamada¹, Toshiko Nozaki Shibata¹, Hiroshi Ito¹, Yoshioki Yamasaki², So Nomoto³, Atsushi Kusaba⁴, Hiroki Yamashita⁴ and Shoichi Ozaki¹, ¹Internal Medicine, St. Marianna University, Kawasaki, Japan, ²Medicine, St. Marianna University, Kawasaki, Japan, ³Department of Orthopedic Surgery and Rheumatology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan, ⁴Institute of Rheumatology, Ebina General Hospital, Ebina, Japan
Background/Purpose: During isometric exercise, the synovial joint tissue is prone to hypoxia, which is further enhanced in the presence of synovial inflammation. Hypoxia is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].